The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Abbvie
Stock and Other Ownership Interests - AbbVie
Telisotuzumab adizutecan (ABBV-400; Temab-A) monotherapy vs trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer with increased c-Met protein expression: An open-label, randomized, phase 3 trial.
 
John Strickler
Stock and Other Ownership Interests - Triumvira Immunologics, Inc
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; GE Healthcare; GlaxoSmithKline; Incyte; Ipsen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Leap Therapeutics; Lilly; Merck; Natera (Inst); Pfizer; Quanta Therapeutics; Regeneron; Roche/Genentech; Sanofi; Seagen; Taiho Oncology; Takeda; Xilio Therapeutics
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); Apollo Therapeutics; AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Lilly (Inst); Novartis; Pfizer; Quanta Therapeutics (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst)
Expert Testimony - Seagen
 
Akihito Kawazoe
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - MSD; Revolution Medicines; Zymeworks
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Jian Li
No Relationships to Disclose
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Hua Fang
No Relationships to Disclose
 
Martha Neagu Aristide
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Patents, Royalties, Other Intellectual Property - Am on patent applications for IAs I worked on at AbbVie (Inst)
 
Athanasios Vasilopoulos
No Relationships to Disclose
 
Yunxia Sui
Stock and Other Ownership Interests - Abbvie
 
Rabih Saab
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Carla Biesdorf de Almeida
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Kanwal Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)